Cooperation with medical experts
Collaboration with Priv.-Doz. Dr. med. Lars Müller and Mr. Saher Tatour – Newsletter sixth release – As a company dedicated to developing innovative technologies to optimise vein punctures, we are …
Aims to support medical staff to automatically puncture a suitable blood vessel for blood collection, medication or intravenous transfusions in hospitals, clinics, diagnostic centers, and blood banks
A gentle method for accurate vein and artery detection and localization to map the needle insertion without human contact
For automated needle adjustment with a machine-learning algorithm for better needle penetration accuracy to puncture the suitable vein or artery
With patent application in the most important global markets
For various types of venipunctures, with specific needles designed for different purposes
Excagol medtech is developing an automated venipuncture device that will take on the most common invasive activity in healthcare centers: EVA, the electronic venipuncture apparatus. Medical personnel can perform punctures efficiently, safely and stress-free with EVA, the mobile computer-controlled system. Vascular structures are made visible by ultrasonic waves. An image processing algorithm recognizes vessels and recommends a suitable target for puncture. After the operator’s confirmation, the needle is automatically steered and precisely puncture the target.
Excagol’s Vision is to become the healthcare industry’s next-generation solution for various puncture purposes for both patients with difficult-to-reach veins and medical personnel with different professional experience.
Venous access is the most common invasive medical procedure and the success rate is unacceptably low: Only about 75% of all venipunctures are successful at the first attempt, often three or more attempts are necessary.
Excagol aims to reduce the failure rate from 25% at the first attempt in the manual process to 5% in the automated process.
Excagol targets the global blood collection market. According to Grand View Research, the blood collection market reached USD 8.5 Billion in 2018 and is projected to reach USD 13.99 Billion by 2026, growing at a CAGR of 6.6%. Excagol targets the venipuncture product market which is projected to reach over USD 962.7 Million by 2026, growing at a CAGR of 3.2% from 2021 to 2026.
MSc Eilon Netzer – CEO & Product Manager
Grad. BA Martin Bukowski – Product & Business Manager
MSc Van Nguyen – Product Marketing & Quality Manager
MSc Nicola Dobler – Marketing & Product Management
BSc Lawrence Netzer – Software & Hardware Development Engineer
MSc Markus Dieckmann – Software & Hardware Development Engineer
MSc Josephine Rodrigues – Software & Hardware Development Engineer
Private Lecturer MD Lars Mueller – Specialist for surgery and visceral surgery, phlebology and vein healing & head of vascular department at Dermatologikum Hamburg
Collaboration with Priv.-Doz. Dr. med. Lars Müller and Mr. Saher Tatour – Newsletter sixth release – As a company dedicated to developing innovative technologies to optimise vein punctures, we are …
Vor etwa zweieinhalb Jahren stellten wir erstmals das Startup Excagol vor, das ein Gerät erfunden hat, welches dabei hilft, bei der Blutabnahme die Vene zu treffen. Bekanntlich dauern in der Medizintechnik …
Newsletter fifth release – Operational test of the semi-automated venipuncture automate
Newsletter fourth release – Identification of blood vessels on ultrasound images using deep learning
Newsletter third release – Development of a prototype for a semi-automated venipuncture automate
Newsletter second release – Acceptance of the Electronic Venipuncture Automate
Subscribe to our Newsletter ! We are able to respond to any messages sent to newsletter@excagol-medtech.com
The R&D team at excagol just achieved a new development stage of image processing analysis which has been successfully tested. Further product development in the process 🚀
Thanks to Life Science Nord for publishing the following article about excagol: https://lifesciencenord.de/de/news/detail/excagol-medtech-stellt-sich-vor.html Life Science Nord begrüßt das Medtech-Start-up herzlich als neues Mitglied im Förderverein! Die excagol medtech ist ein Hamburger Start-up, …
The talk Netzer has given during the last interview about excagol:
Subscribe to our free monthly Newsletter
We can create a smooth business that will give significant financial benefits to both investors and us. With resources, we will be able to afford more full-time employees and buy necessary equipment.